Table 1.
The characteristics of study subjects and prevalence of HPV DNA status in breast cancer patients and noncancer controls.
| Parameter | Casesa (N = 79) | Controlsa (N = 51) | P-value |
|---|---|---|---|
| Age (year ± SD) | 47.77 ± 12.552 | 34.20 ± 9.704 | ≤0.0001 (t-test) |
|
| |||
| HPV | 0.002 | ||
| Positive | 15 (25.9)b | 1 (2.4) | O R 13.953 |
| Negative | 43 (74.1) | 40 (97.6) | (95% CI 1.762–110.526) |
|
| |||
| HPV genotype (% within type) | |||
| HPV-124 | 1 (6.25) | 1 (100) | |
| HPV-23 | 2 (12.5) | ||
| HPV-18 | 4 (25) | ||
| HPV-16 | 4 (25) | ||
| HPV-15 | 1 (6.25) | ||
| HPV-11 | 1 (6.25) | ||
| HPV-6 | 2 (12.5) | ||
| Unknown | 1 (6.25) | ||
|
| |||
| HPV genotype (% within subjects) | |||
| High-risk type | 8 (14) | 0 | 0.005 |
| Low-risk type | 6 (10.5) | 1 (2.4) | |
| Negative | 43 (75.5) | 40 (97.6) | |
|
| |||
| HPV genotype (% within subjects) | |||
| Mucosal type | 11 (19) | 0 | 0.002 |
| EV-cutaneous type | 4 (6.9) | 1 (2.4) | |
| Negative | 43 (74.1) | 40 (97.6) | |
|
| |||
| Tumor type (% within tumor type) | |||
| IDC | 67 (84.8) | ||
| ILC | 8 (10.1) | ||
| IDC-ILC mix | 1 (1.3) | ||
| MC | 2 (2.5) | ||
| DC | 1 (1.3) | ||
aSome of the subjects have been considered as missing value after quality examination of nucleic acid extraction.
bNumbers in parentheses are percentages.